Monoclonal antibodies.
The development of hybridoma monoclonal antibody (MAb) technology has had a major impact on clinical and laboratory medicine. It has allowed the production of essentially unlimited quantities of pure, homogeneous antibodies against a large variety of antigens. Despite the many advantages of MAbs, the effort and expense required for their production is not always justified. Less expensive and more easily obtained conventional anti-serum is still perfectly adequate in some instances. Nevertheless, murine MAbs have found widespread use in clinical and research laboratories, particularly in the field of oncology. Considerable effort has been devoted to the development of human MAbs, since antibodies of human origin are expected to be superior in therapeutic and in vivo diagnostic settings. However, technical difficulties currently prevent their widespread use. Finally, novel approaches using genetic engineering techniques are described, which portend exciting new developments in the near future.
S P
SP
Cole
Hybridoma. 1985 Fall;4(3):211-22
3930388
J Biol Response Mod. 1986 Oct;5(5):379-93
3534144
Biochem J. 1981 Oct 15;200(1):1-10
7036988
Nature. 1984 Dec 13-19;312(5995):604-8
6095112
Nature. 1984 Dec 13-19;312(5995):643-6
6095115
Nature. 1985 Mar 21-27;314(6008):268-70
2580239
Cancer Res. 1986 Jul;46(7):3225-38
3518915
Nature. 1975 Aug 7;256(5517):495-7
1172191
J Immunol. 1986 Aug 1;137(3):1066-74
3088107
Cancer Res. 1985 Nov;45(11 Pt 2):5769-80
2413997
Lancet. 1983 Feb 19;1(8321):386-8
6130380
J Clin Oncol. 1985 Mar;3(3):340-52
3973645
FEBS Lett. 1985 Mar 25;182(2):278-80
3979550
J Exp Med. 1965 Mar 1;121:439-62
14270243
J Immunol. 1985 Aug;135(2):1530-5
3874237
Lancet. 1982 Apr 3;1(8275):762-5
6121224